Cibus director Gerhard Prante sells $2,978 in stock

Published 01/24/2025, 04:17 PM
CBUS
-

SAN DIEGO—Cibus, Inc. (NASDAQ:CBUS) Director Gerhard Prante recently sold 1,150 shares of Class A Common Stock, according to a filing with the Securities and Exchange Commission. The shares were sold at a price of $2.59 each, totaling approximately $2,978. The transaction comes as the stock trades near $2.42, down 84% over the past year. According to InvestingPro data, analysts have set price targets ranging from $4 to $25 for the company, which currently has a market capitalization of $89 million.

Following this transaction, Prante now holds 34,157 shares directly. The sale was executed automatically as part of a Rule 10b5-1 trading plan that Prante had adopted on August 16, 2024. This plan allows insiders to set up a predetermined schedule for selling stocks, providing a degree of insulation from potential accusations of insider trading. InvestingPro analysis suggests the stock is currently undervalued, with 12 additional ProTips available to subscribers ahead of the company's next earnings report on February 28, 2025.

In other recent news, Cibus Inc. has seen significant developments. Canaccord Genuity analysts revised their price target for Cibus, reducing it from $20.00 to $18.00, while maintaining a Buy rating. In a parallel move, Jefferies also adjusted its price target for Cibus, lowering it to $5.00 from $8.00, but retained its Hold rating.

Cibus has announced plans to raise approximately $22.6 million through a direct stock offering of about 9 million shares. The raised capital is expected to fund the advancement of Cibus's gene-edited plant productivity traits and further development of its soybean platform. The company also disclosed a new base salary of $320,000 for executive Carlo Broos, signaling a change in the compensation arrangement.

Despite reporting a net loss of $201.5 million, Cibus anticipates earning $200 million annually in royalties from rice traits in the U.S. and an additional $150 million from expansion into Asian markets. These are recent developments that aim to enhance the company's growth and sustainability through gene editing in the agricultural sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.